MacroGenics, Takeda deal

Takeda terminated its option agreement and returned rights to bispecific antibody MGD010 to MacroGenics. The companies said the decision was not related to an ongoing Phase I trial of the candidate to treat autoimmune disorders and was part of a broader strategic shift for Takeda.

In July, Takeda said it will “reduce and concentrate” its R&D in Japan and the U.S. In recent years, the pharma has winnowed down its disease focus to CNS, cancer and gastrointestinal disease, plus vaccines. ...